Q&A: Using Effective Treatments Earlier for NSCLC
“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”
Read MoreJan 1, 2024
“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”
Read MoreDec 6, 2023
Do you remember the eNSCLC research presented at ESMO? Test your knowledge now!
Read MoreNov 30, 2023
A curated eBook featuring ESMO 2023: eNSCLC-focused studies, findings, and expert opinions.
Read MoreNov 14, 2023
Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.
Read MoreNov 14, 2023
Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.
Read MoreNov 2, 2023
“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”
Read MoreOct 31, 2023
Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.
Read MoreOct 16, 2023
For a retrospective study involving 607 oncology patients treated from 2014-2019, the potential for predicting patient prognosis and guiding immunotherapy treatment through the analysis of total tumor volume (TTV) and artificial intelligence (AI) tumor heterogeneity from CT scans was investigated.
Read MoreOct 16, 2023
In early-stage non-small cell lung cancer (NSCLC), the recommended treatment options include targeted and immune therapies.
Read MoreOct 16, 2023
In the management of early-stage non-small cell lung cancer (eNSCLC), the introduction of PD-1/PD-L1 checkpoint inhibitors has marked a significant advancement.
Read MoreOct 16, 2023
Cancer-associated fibroblasts (CAFs) constitute a critical element of the tumor microenvironment, and TGFβ-induced CAFs have been implicated in poor prognosis across various indications.
Read MoreOct 16, 2023
One of ESMO’s most popular track is its Young Oncologist Track designed and initiated by the ESMO Young Oncologist Committee.
Read MoreOct 16, 2023
There are more than 50 satellite symposia sessions taking place at ESMO. Follow PW for conference coverage.
Read MoreOct 16, 2023
Take a look at ESMO’s keynote sessions and full schedule. Follow PW for conference coverage.
Read More